

[\(INDEX.PHP\)](#)

Intellectual Property

[HOME \(INDEX.PHP\)](#)[ABOUT ERS \(ABOUT-ERS.PHP\)](#)[INTELLECTUAL PROPERTY \(INTELLECTUAL-PROPERTY.PHP\)](#)[LICENSING \(LICENSING.PHP\)](#)[CRISPR-CAS9 TECHNOLOGY \(CRISPR-CAS-9-TECHNOLOGY.PHP\)](#)[NEWS \(NEWS.PHP\)](#)

CHARPENTIER / UC BERKELEY INTELLECTUAL PROPERTY

ERS Genomics holds an exclusive worldwide license from Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR-Cas9 ([crispr-cas-9-technology.php](#)) for all applications other than use as a human therapeutic. This patent application has broad and dominant claims covering CRISPR-Cas9 compositions and methods of genome editing in any organism.

A license ([licensing.php](#)) to this foundational intellectual property will be required for commercialization of research tools, kits, reagents, and genetically modified cell lines and organisms.

Patent application number PCT/US2013/032589, entitled, "Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription."

(<http://www.google.com/patents/WO2013176772A1?cl=en>)

ERS Genomics Limited, 88 Harcourt Street, Dublin 2, Ireland | info@ersgenomics.com (<mailto:info@ersgenomics.com>)



© 2015 ERS Genomics